Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa

Pallerla, Srinivas Reddy, Elion Assiana, Darrel Ornelle, Linh, Le Thi Kieu , Cho, Frederick Nchang, Meyer, Christian G., Fagbemi, Kaossarath Adédjokè, Adegnika, Ayola Akim, Beng, Véronique Penlap, Achidi, Eric A., Kahunu, Gauthier Mesia, Bates, Matthew, Grobusch, Martin P., Kremsner, Peter G., Ntoumi, Francine and Velavan, Thirumalaisamy P. (2021) Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa. International Journal of Infectious Diseases, 104 . pp. 207-213. ISSN 1201-9712

Full content URL: https://doi.org/10.1016/j.ijid.2020.12.009

Documents
Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa
Published Open Access manuscript
[img]
[Download]
[img]
Preview
PDF
Pallerla et al... IJID 2021.pdf - Whole Document
Available under License Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.

396kB
Item Type:Article
Item Status:Live Archive

Abstract

Background: HIV-infection, tuberculosis and malaria are the big three communicable diseases that plague sub-Saharan Africa. If these diseases occur as co-morbidities they require polypharmacy, which may lead to severe drug-drug-gene interactions and variation in adverse drug reactions, but also in treatment outcomes. Polymorphisms in genes encoding drug-metabolizing enzymes are the major cause of these variations, but such polymorphisms may support the prediction of drug efficacy and toxicity. There is little information on allele frequencies of pharmacogenetic variants of enzymes involved in the metabolism of drugs used to treat HIV-infection, TB and malaria in the Republic of Congo (ROC). The aim of this study was therefore to investigate the occurrence and allele frequencies of 32 pharmacogenetic variants localized in absorption distribution, metabolism and excretion (ADME) and non-ADME genes and to compare the frequencies with population data of Africans and non-Africans derived from the 1000 Genomes Project.

Results: We found significant differences in the allele frequencies of many of the variants when comparing the findings from ROC with those of non-African populations. On the other hand, only a few variants showed significant differences in their allele frequencies when comparing ROC with other African populations. In addition, considerable differences in the allele frequencies of the pharmacogenetic variants among the African populations were observed.

Conclusions: The findings contribute to the understanding of pharmacogenetic variants involved in the metabolism of drugs used to treat HIV-infection, TB and malaria in ROC and their diversity in different populations. Such knowledge helps to predict drug efficacy, toxicity and ADRs and to inform individual and population-based decisions.

Keywords:Malaria, Pharmacogenetics, Republic of Congo, Tuberculosis
Subjects:C Biological Sciences > C420 Human Genetics
A Medicine and Dentistry > A300 Clinical Medicine
C Biological Sciences > C410 Applied Genetics
C Biological Sciences > C521 Medical Microbiology
C Biological Sciences > C500 Microbiology
Divisions:College of Science > School of Life Sciences
ID Code:44153
Deposited On:23 Mar 2021 11:21

Repository Staff Only: item control page